glp-1 news oct 21 2025 obesity drug october Perspectives from employers on the costs and issues associated with covering agonists for weight loss Eli Lilly to seek approval – Regulating a "Miracle Drug": GLP-1

In our view, the main research gap in current antioxidant testing lies in the insufficient awareness of these limitations and excessive reliance on such results

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the PIONEER trials

Whether you are struggling with an injury, chronic inflammation, or simply seeking to optimize your well-being, BPC-157 offers a promising avenue for healing and regeneration

10.15252/embr.202357413 85 NegreiraG

For patients seeing skin laxity alongside fat loss, this stack addresses both processes simultaneously

Here at The Feed, we want you to love your experience and the sports nutrition products you purchase